These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 25964967)

  • 21. Landmarks in hormonal therapy for prostate cancer.
    Hammerer P; Madersbacher S
    BJU Int; 2012 Oct; 110 Suppl 1():23-9. PubMed ID: 23046037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Castration of prostate cancer patients and cognition].
    Portin R; Koskinen A; Helenius H; Nurmi M; Salminen E
    Duodecim; 2005; 121(16):1784-5. PubMed ID: 16268226
    [No Abstract]   [Full Text] [Related]  

  • 23. [Therapeutic options in hormone refractory prostate carcinoma].
    Graefen M; Hammerer P; Haese A; Huland H
    Urologe A; 2000 May; 39(3):267-73. PubMed ID: 10872254
    [No Abstract]   [Full Text] [Related]  

  • 24. Revisiting the ultimate target of treatment for prostate cancer.
    Dahut WL; Madan RA
    Lancet; 2010 Apr; 375(9724):1409-10. PubMed ID: 20398924
    [No Abstract]   [Full Text] [Related]  

  • 25. [2017 ASCO: Complete androgen blockade strikes back].
    Penel N
    Bull Cancer; 2017; 104(7-8):599-601. PubMed ID: 28688745
    [No Abstract]   [Full Text] [Related]  

  • 26. Long-term Efficacy and Safety Results: Can Enzalutamide Challenge the Dogma of Androgen Deprivation Therapy in Hormone-naïve Prostate Cancer?
    Albiges L; Loriot Y; Massard C; Fizazi K
    Eur Urol; 2015 Nov; 68(5):802-4. PubMed ID: 25922192
    [No Abstract]   [Full Text] [Related]  

  • 27. Androgen deprivation therapy and cognitive impairment?
    Bagcchi S
    Lancet Oncol; 2015 Jul; 16(7):e314. PubMed ID: 26004374
    [No Abstract]   [Full Text] [Related]  

  • 28. The role of enzalutamide in the treatment of castration-resistant prostate cancer.
    Rawlinson A; Mohammed A; Miller M; Kunkler R
    Future Oncol; 2012 Sep; 8(9):1073-81. PubMed ID: 23030482
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Hormonal treatment of cancer of the prostate: review and present status].
    Ganzer R; Wieland WF; Bach T; Rössler W; Blana A
    Dtsch Med Wochenschr; 2007 Jan; 132(4):161-6. PubMed ID: 17230333
    [No Abstract]   [Full Text] [Related]  

  • 30. [Hormone therapy of locally advanced and metastatic prostate carcinoma].
    Rübben H
    Praxis (Bern 1994); 2001 Sep; 90(38):1641-4. PubMed ID: 11675917
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Case records of the Massachusetts General Hospital. Case 16-2011. A 67-year-old man with recurrent prostate cancer.
    Smith MR; Zietman AL; Finkelstein JS; Wu CL
    N Engl J Med; 2011 May; 364(21):2044-51. PubMed ID: 21612474
    [No Abstract]   [Full Text] [Related]  

  • 32. [An active sex life is possible for men undergoing androgen deprivation therapy for prostate cancer].
    Fode M; Østergren P; Jensen CF; Azawi N; Frey A; Sønksen J
    Ugeskr Laeger; 2015 Jun; 177(24):. PubMed ID: 26058525
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enzalutamide in metastatic prostate cancer before chemotherapy.
    Froehner M; Wirth MP
    N Engl J Med; 2014 Oct; 371(18):1755. PubMed ID: 25354112
    [No Abstract]   [Full Text] [Related]  

  • 34. Enzalutamide in metastatic prostate cancer before chemotherapy.
    Beer TM; Tombal B
    N Engl J Med; 2014 Oct; 371(18):1755-6. PubMed ID: 25354111
    [No Abstract]   [Full Text] [Related]  

  • 35. [Hot flushes in men after surgical or pharmacologic castration].
    Aubert J; Vigouroux V; Doré B
    Prog Urol; 1995 Sep; 5(4):507-9. PubMed ID: 7581499
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The molecular mechanisms of resistance to androgen deprivation therapy in prostate cancer].
    Kosaka T; Oya M
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():353-9. PubMed ID: 23513865
    [No Abstract]   [Full Text] [Related]  

  • 37. Landmarks in hormonal therapy for prostate cancer.
    Tombal B; Crawford ED
    BJU Int; 2013 Mar; 111(3):E12-3. PubMed ID: 23444930
    [No Abstract]   [Full Text] [Related]  

  • 38. Prostate cancer: enzalutamide PREVAILs.
    Payton S
    Nat Rev Urol; 2014 Jul; 11(7):361. PubMed ID: 24934449
    [No Abstract]   [Full Text] [Related]  

  • 39. Impact of alternative antiandrogen therapy for Japanese prostate cancer patients in the era of new hormonal therapy.
    Nakata W; Yamamichi G; Tsujimura G; Tsujimoto Y; Nin M; Tsujihata M
    Int J Urol; 2020 Jan; 27(1):87-89. PubMed ID: 31602723
    [No Abstract]   [Full Text] [Related]  

  • 40. Reply: Landmarks in hormonal therapy for prostate cancer.
    Hammerer P; Madersbacher S
    BJU Int; 2013 Mar; 111(3):E13-5. PubMed ID: 23444931
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.